(GOTHENBURG, Sweden / SAN FRANCISCO, CA, October 30, 2018) – Heliospectra AB (publ) (OTCQB: HLSPY, FIRSTNORTH: HELIO), a world leader in intelligent lighting technology for greenhouse and controlled plant growth environments, announces a new order from a leading medicinal plant research facility in Spain. The research facility is a privately-owned Spanish company founded in 2008 and active in the field of phytotherapy research. The order is for Heliospectra's fully adjustable ELIXIA LED lighting solution and valued at SEK 1.2 million (EUR 117,855).
Heliospectra's ELIXIA creates clear business benefits for cultivation teams and researchers around the world. The fully adjustable LED lighting solution is compatible with Heliospectra's helioCORE™ light control software, enabling growers to improve the quality of plants and accelerate harvest and production cycles while providing consistent and standardized returns 365 days a year.
The order will be visible in the accounts and delivered in Q4 2018.
Ali Ahmadian, CEO of Heliospectra | +46 (0)72 203 6344 | [email protected]
Redeye is Heliospectra Certified Advisor for Nasdaq First North - www.redeye.se
Heliospectra AB (publ) (OTCQB: HLS, FIRST NORTH: HELIO) is the global leader in intelligent lighting technology, light control systems and related services for greenhouse and controlled plant growth environments. With the vision to make commercial crop production more connected and resource-efficient, Heliospectra integrates customized LED spectral strategies with real-time response and artificial intelligence to create predictable and reliable business forecasts and harvest results. Founded in 2006, Heliospectra is committed to helping growers and commercial producers across six continents consistently increase yields and produce crops with quality appearance, superior nutritional or medicinal value and longer shelf life, harvest after harvest. Heliospectra is the recipient of multiple international awards and recognitions. For more information, please visit https://www.heliospectra.com.
The statements in this press release constitute forward-looking statements within the meaning of federal securities laws. Such statements are based on our current beliefs and expectations and are inherently subject to significant business, economic and competitive uncertainties and contingencies, many of which are beyond our control. In addition, such forward-looking statements are subject to assumptions with respect to future business strategies and decisions that are subject to change. Potential risks and uncertainties include, but are not limited to, technical advances in the industry as well as political and economic conditions present within the industry. We do not take any obligation to update any forward-looking statement to reflect events or developments after a forward-looking statement was made.
This information is information that Heliospectra AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 15:00 CEST / 8:00 AM CDT on October 30th 2018.